SecBot SecBot
SC 13G ·Filed Nov 13, 2026

YARW

Yarrow Bioscience, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed3d 23h ago SEC0000902664-26-004528
Passive investor 5%+ stake
Actionable Insight • Neutral

Monitor for any subsequent 13D conversion or stake increases by Spruce Street, though the passive certification makes activist intent unlikely. The accumulation of passive stakes by multiple funds post-offering suggests institutional interest in Yarrow's Phase 2a Graves disease trial, with topline results expected in H2 2027.

DirectionNeutral
Confidencehigh
Horizonweeks

YB-101

◆ Mixed Named in this SC 13G
Impact
Phase
Phase 2a/2b (dosing initiated ~July 27, 2026); Phase 1 SAD in thyroid eye disease previously reported
Time to market
Unknown — mid-stage. If the Phase 2a/2b trial succeeds and later registrational studies follow, approval would be several years away (late 2020s at the earliest); the company currently has no approved products.
Next catalyst
None dated

What to watchYB-101 is a Phase 2a/2b, single-asset bet at a company (Nasdaq: YARW, formerly VYNE) that just closed a reverse merger, raised ~$200M, and began dosing the pivotal-to-next-stage trial, but the defining data readout is not expected until 2H 2027. A non-medical investor should treat YARW as a speculative, liquidity-thin clinical stock: watch for interim Phase 2a/2b data, the exact readout date, and any competitive readouts from anti-FcRn/IgG-degrading drugs in Graves'/thyroid eye disease.

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Spruce Street Capital LP filed a Schedule 13G disclosing a 6.4% passive stake in Yarrow Bioscience, representing 607,382 shares as of September 30, 2026. This is a new filing by Spruce Street, adding to a series of recent 13G filings by other institutional investors (Bellevue Group at 10.6%, Invus Global at 7.2%) following Yarrow's September 2026 equity offering. The passive certification and hedge fund identity suggest a routine investment, not an activist precursor.

Key Financial Metrics

Stake
6.4%
Investor
Spruce Street Capital LP
Investor Type
hedge fund

Key Facts

  • Spruce Street Capital LP disclosed a 6.4% passive stake in Yarrow Bioscience, representing 607,382 shares
  • Stake based on 9,437,693 shares outstanding as of September 14, 2026, after the company's public offering
  • Filing certifies passive intent under Rule 13d-1(b), with no intention to influence control
  • This is a new 13G filing, not an amendment to a prior filing
  • Spruce Street is a hedge fund based in New York, NY

Financial Impact

6.4% stake valued at approximately $10.8M based on $168M market cap

ownership

Risk Factors

  • Passive certification could be converted to active (13D) if Spruce Street changes intent, though no indication of this
  • Concentration of institutional ownership may increase stock volatility on trial results

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G Filing (Primary)0000902664-26-004528
Document: 0000902664-26-004528-index-headers.html0000902664-26-004528
Document: 0000902664-26-004528-index.html0000902664-26-004528
Document: 0000902664-26-004528.txt0000902664-26-004528

Track record

13 reports on YARW

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 17, 2026today SC 13G/A Neutral 3/10 Entry $13.93 Now $14.27 +2.44% settles Dec 16
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $14.20 Now $14.27 +0.49% settles Dec 16
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $13.93 Now $14.27 +2.44% settles Dec 16
  4. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $13.93 Now $14.27 +2.44% settles Dec 16
  5. Nov 16, 20261d ago SC 13G/A Neutral 3/10 Entry $15.44 Now $14.27 −7.58% settles Dec 15
  6. Nov 16, 20261d ago SC 13G Neutral 3/10 Entry $18.20 Now $14.27 −21.59% settles Dec 15
  7. Nov 16, 20261d ago SC 13G/A Neutral 3/10 Entry $18.03 Now $14.27 −20.85% settles Dec 15
  8. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $17.35 Now $14.27 −17.75% settles Dec 15
  9. Nov 13, 20263d ago SC 13G Neutral 3/10 Viewing Entry $18.03 Now $14.27 −20.85% settles Dec 15
  10. Nov 12, 20265d ago 8-K Neutral 4/10 Entry $19.63 Now $14.27 −27.31% settles Dec 11
Showing 10 of 13

US Market Status

Market Open · Closes in 22m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026